FDA Accepts CSL Behring’s Biologics License Application for Etranacogene Dezaparvovec for Priority Review  

Global biotherapeutics leader CSL Behring, a business of CSL, announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), for priority review, for etranacogene dezaparvovec (also known as CSL222), an investigational gene therapy for the treatment of adults with hemophilia B. Etranacogene dezaparvovec was specifically designed to make near-normal […]

uniQure and CSL Behring Achieve Primary Endpoint in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B

Press release source: uniQure and CSL Behring via Globe Newswire CSL Behring, a global biotherapeutics leader, and uniQure N.V., a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that etranacogene dezaparvovec, an investigational adeno-associated virus five (AAV5)-based gene therapy for the treatment of patients with severe to moderately […]

CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec

Read the full press release from CSL Behring here. Global biotherapeutics leader CSL Behring announced the closing of its global Commercialization and License agreement with uniQure for etranacogene dezaparvovec, a novel gene therapy for the treatment of hemophilia B. Etranacogene dezaparvovec is currently in Phase 3 clinical trials and has been shown  to result in near-normal […]